Jun 24, 2025 3-5pm ET
Tuesday on The Robert Scott Bell Show:
Hour 1
‘Heartbreaking’: Jury Sides With Hospital in 2021 Death of 19‑Year‑Old Admitted for COVID A Wisconsin jury ruled in favor of Ascension St. Elizabeth Hospital, Dr. Gavin Shokar, and nurse Hollee McInnis in a wrongful death case involving Grace Schara, a 19-year-old with Down syndrome who died in 2021 after being hospitalized with COVID-19. The Schara family alleged that the hospital implemented a Do Not Resuscitate (DNR) order without their consent and administered a combination of sedatives—Precedex, lorazepam, and morphine—that they believe caused Grace’s death. They argued that Grace was not in critical condition when admitted and that her decline resulted from medical interventions rather than the virus itself. After a short deliberation, the jury found no evidence of negligence, battery, or failure to obtain informed consent. The family expressed deep disappointment in the verdict, maintaining that key decisions were made without their knowledge and in violation of Grace’s rights. The trial highlighted broader concerns about hospital protocols during the pandemic, including patient isolation, use of sedation, and the removal of family members from the care environment. Expert testimony indicated that separating Grace from her father may have worsened her respiratory status. The case also reignited debate over Wisconsin’s $750,000 malpractice cap, which critics say limits families’ access to justice. Although the Scharas lost the case, they pledged to continue advocating for transparency in hospital practices, medical freedom, and reforms to protect patients with disabilities and their families from similar experiences.
Special Guest: Judy Mikovits
Dr Mikovits earned a BA in Chemistry from University of Virginia in 1980 and a PhD in Biochemistry and Molecular Biology from George Washington University in 1992. In her forty-year quest to understand the causes, prevent and treat chronic diseases, she has co-authored seminal papers culminating at least a decade of research in each of four fields: immunology, natural products chemistry, epigenetics, and HIV/AIDs drug development.
In 2009 Dr Mikovits led the team that first isolated and characterized a new family of human disease-associated retroviruses, XMRVs/HGRVS. Dr Mikovits has co-authored more than 50 peer reviewed publications and book chapters; holds patent # WO 2012061790 A1. “Combination Therapy for Prostate Cancer using Botanical Compositions and Bicalutamide”.
Dr Mikovits is a New York Times Best selling author of the books, Plague Plague of Corruption and the Case Against the Masks and Ending Plague.The formation of M.A.R.C. Inc. in 2016 with colleague, Dr. Frank Ruscetti, has afforded Dr. Mikovits the opportunity to come full-circle back to her first love, natural products chemistry. In 2020 MARC Inc evolved to become DrJsolutions a company focused not only on education but on providing solutions for prevention and treatment autoimmune/auto-inflammatory diseases resulting from viral infection, drugs and environmental toxins. Her heart and passion is to focus on natural products chemistry and plant based drug therapies.
Her current focus is on medical cannabis with breakthroughs in understanding of the pathophysiology of neuroimmune diseases as acquired endocannabinoid immune dysfunction (AEIDS) including COVID19.
Welcome back to another “Homeopathic Hits” episode on The Robert Scott Bell Show!
Today’s spotlight is on Guaiacum Officinale—a botanical powerhouse for chronic joint stiffness, gouty pain, and deep bone aches linked to long-standing toxicity or infection.
When joints feel locked and bones throb with ache, this remedy may help break the chains.
Download the Information Sheet
Hour 2
Cancer Patients Are Overmedicated To Enrich Health Systems, Study Claims A new study in The Journal of Health Economics reveals that cancer patients treated by physicians participating in the 340B Drug Pricing Program receive significantly more medications—both in volume and intensity—than comparable patients not in the program, suggesting that health systems may be overprescribing to maximize revenue. The likelihood of prescribing outpatient drugs per patient has increased by over 25% in 340B-affiliated practices, and treatment intensity has similarly surged. While the program was originally designed to help underinsured patients by allowing hospitals to purchase medications at reduced cost, critics argue that financial incentives have skewed prescribing patterns, potentially exposing patients to unnecessary side effects, drug interactions, and higher costs. This trend raises broader concerns about low-value care and overdiagnosis in healthcare, where excessive screening and treatment offer limited or no benefit and may cause harm. The study calls for increased transparency, stronger oversight, and policy reform to ensure that the 340B program meets its original mission without encouraging overutilization.
‘Forever Chemical’ Found in Breads and Cereals — Even in Organic Products A joint study by Global 2000 and PAN Europe detected widespread contamination of trifluoroacetic acid (TFA)—a breakdown product of PFAS pesticides and refrigerants—in 48 cereal-based products, including baked goods, pasta, flours, and breakfast cereals, with levels ranging from 13 µg/kg up to 420 µg/kg. Critically, both conventionally grown and organic items showed high TFA concentrations—median levels of 165 µg/kg and 47 µg/kg respectively—indicating that contamination is systemic and cannot be avoided through organic farming. This marks a significant increase from baseline studies in 2016–17 and aligns with concerns about TFA’s persistence in water, soil, and now food chains. TFA’s classification as a reproductive toxicant in Europe and its designation as a “forever chemical” highlights its environmental stability and potential health risks, including endocrine disruption and bioaccumulation. The findings underscore the urgent need to regulate PFAS use in agriculture and industry, strengthen food safety oversight, and safeguard vulnerable populations, especially children.
Texas Gov. Abbott Vetoes Bill That Would Ban All THC Products Texas Governor Greg Abbott has vetoed legislation that sought to prohibit all products containing tetrahydrocannabinol (THC), the psychoactive compound in cannabis, effectively blocking a move that would have banned hemp-derived edibles, vapes, and other consumer goods. Supporters of the bill argued that recent spikes in underage THC consumption and related hospitalizations warranted a total ban, but critics cautioned that such a sweeping measure could criminalize everyday products like lotions, gummies, or topicals containing trace cannabinoids. Abbott’s veto reflects concerns about overreach, enforcement challenges, and unintended consequences for adults legally using hemp-derived items under federal law, particularly since the Farm Bill legalized hemp products with less than 0.3% THC. The governor emphasized the need for a nuanced regulatory framework that protects children without infringing on adult consumer rights or hindering a state-approved hemp industry, leaving the door open for more targeted legislative or regulatory solutions in the future.
Experimental Drug Helps Patients Lose Nearly a Quarter of Body Weight in Early Trials Novo Nordisk’s experimental pill, amycretin, demonstrated dramatic early results in Phase 2 trials, with participants losing an average of up to 24.3 percent of their body weight. The drug combines two hunger-regulating hormones into a once-monthly oral dose, marking a significant departure from current GLP‑1 injectables. While precise participant numbers weren’t disclosed, these weight reduction levels approach or surpass those of leading injectable options like Wegovy and Mounjaro, which typically produce 15–20 percent losses. Amycretin’s oral delivery could appeal to patients who find weekly injections inconvenient, potentially improving compliance. However, the trials are small and short-term, and safety data remain limited. Across similar trials, notably Amgen’s monthly injectable MariTide, high weight loss often coincides with gastrointestinal side effects; in MariTide’s case, up to 90 percent of participants experienced issues like nausea, prompting dose-adjustment protocols in Phase 3 studies. Analysts caution that while oral delivery may enhance convenience, long-term tolerance and sustained efficacy must be confirmed before amycretin enters larger clinical testing or regulatory review. Still, the early success signals a potential paradigm shift in obesity pharmacotherapy, especially if pill-based GLP‑1–style drugs can overcome the limitations of current injectables and expand access to effective weight loss treatments.
Diabetic Patients Taking GLP‑1s May Face Increased Risk of Eye Disease, Study Suggests A large observational study published in JAMA Ophthalmology analyzed nearly 140,000 older adults with diabetes and found that those using long-duration GLP‑1 receptor agonists—drugs like semaglutide and tirzepatide—had approximately double the risk of developing neovascular age-related macular degeneration (nAMD) compared to non-users (0.2 percent vs. 0.1 percent after one year). While the absolute risk remains small, the relative increase raises concerns given GLP‑1s’ widespread use for diabetes and weight management. Researchers hypothesize that GLP‑1 receptors in the retina may contribute to disease progression. Canadian data also suggest risk increases with longer use and higher doses, particularly in patients with additional risk factors such as prior stroke. Experts note that previous case reports have linked GLP‑1 therapies to serious ocular conditions like nonarteritic anterior ischemic optic neuropathy and papillitis. Given these findings, clinicians are advised to monitor patients on GLP‑1s for visual symptoms—such as blurred vision or central vision loss—and consider ophthalmologic exams, particularly in older adults. Despite the concern, supporters of GLP‑1 therapies emphasize their substantial benefits, including improved glycemic control, cardiovascular protection, and weight reduction. The study highlights the importance of personalized risk assessment and vigilance in long-term therapy management.
Study: More Microplastics in Glass Bottles Than Plastic France’s food safety agency ANSES conducted a comprehensive survey of 48 beverage products—including soda, iced tea, beer, and lemonade—and found glass-bottled drinks contained an average of 100 microplastic particles per liter, up to 50 times more than those in plastic or metal containers. Caps painted with plastic coatings were identified as the primary contamination source: friction during storage scratches off paint particles that leach into the liquids. Lighter beverages like water and wine showed lower contamination levels (around 4.5 particles per liter in glass vs. 1.6 in plastic). This unexpected result overturned common assumptions that glass bottles provide a safer packaging medium, potentially exposing consumers to microplastics linked to inflammation, endocrine disruption, and cancer in animal models. Although health risk thresholds for microplastic consumption remain undefined, ANSES recommends preventive measures—such as rinsing or blowing on bottle caps before drinking—to reduce particle intake by up to 60 percent. The study underscores a regulatory blind spot in packaging safety standards and calls for reevaluation of materials used in food and drink packaging, as well as monitoring of microplastic exposure through everyday consumption.
Questions of The Day!
Hi Robert & Super D
My husband is almost 60 and is concerned about losing testosterone. Is there a natural way to rebuild it in his body over getting testosterone hormone shots ?
Thank you
Elizabeth G
I am studying Homeopathy and love what I am learning. I need a Homeopath who can help me work through some issues, ongoing now for 7 months, and regular western medicine hasn’t helped. Need to make an appointment as soon as possible. Can you help me with finding one who is taking clients now?
Thanks in advance for your help. Dr. Buttar always loved your time together.
Norma
